Cybin Investor Relations Material
Latest events
AGM 2025
Cybin
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cybin Inc
Access all reports
Cybin Inc. is a clinical-stage biopharmaceutical company dedicated to developing psychedelic-based therapeutics. The company focuses on creating treatments for mental health conditions through innovative drug discovery platforms, drug delivery systems, and formulation approaches. Cybin is developing a range of proprietary psychedelic molecules, including CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule for generalized anxiety disorder. These efforts are part of Cybin's broader mission to address unmet needs in mental healthcare with novel therapeutic options. The company is headquartered in Toronto, Canada, and its shares are listed on the NYSE.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CYBN
Country
🇺🇸 United States